You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Clinical features of responders to nivolumab

From: Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

n = 72   All Responder Non-responder ORR P-value
Age < 65 26 (36%) 8 18 31% 0.07
≥65 46 (64%) 6 40 13%  
Gender Male 56 (78%) 11 45 20% 0.94
Female 16 (22%) 3 13 19%  
ECOG PS 0 43 (60%) 13 30 30% < 0.01
≥1 29 (40%) 1 28 3%  
Histology Intestinal 31 (43%) 5 26 16% 0.54
Diffuse 41 (57%) 9 32 22%  
Borrmann classification Type4 7 (10%) 0 7 0% 0.17
Others 65 (90%) 14 51 22%  
Number of previous chemotherapy 2 29 (40%) 8 21 28% 0.15
≥3 43 (60%) 6 37 14%  
Site of metastasis Lymph node 59 (82%) 14 45 24% 0.05
Peritoneum 35 (49%) 5 30 14% 0.28
Liver 32 (44%) 4 28 13% 0.18
Lung 10 (14%) 1 9 10% 0.42
Number of metastatic sites 1 21 (29%) 4 17 19% 0.96
≥2 51 (71%) 10 41 20%  
  1. ECOG PS Eastern Cooperative Oncology Group performance status, ORR objective response rate